JB/CALL/MERCK & CO./130/0.0333/20.09.24 Stock

Warrant

MRKAJB

CH1257352083

Market Closed - Swiss Exchange 11:20:00 2024-05-16 EDT
0.22 ^CHF	+4.76%

Current month	-4.35%
3 months	+4.76%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart MERCK & CO., INC.

Chart JB/CALL/MERCK & CO./130/0.0333/20.09.24

Latest news about MERCK & CO., INC.

BioInvent Presents Promising Clinical Efficacy and Safety for anti-TNFR2 agent BI-1808 at ASCO 2024	05-23	AQ
BioInvent Presents Promising Phase 1 Data for BI-1206 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors at ASCO 2024	05-23	AQ
HPV vaccine provides real benefits for men, analysis shows	05-23	RE
MSD collaboration to drive development of solid tumour combination therapy	05-21	AQ

More news

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	MERCK & CO., INC.
Issuer	Bank Julius Bär
	MRKAJB
ISIN	CH1257352083
Date issued	2023-04-12
Strike	130 $
Maturity	2024-09-20 (118 Days)
Parity	30 : 1
Emission price	0.25 CHF
Emission volume	N/A
Settlement	cash
Currency	CHF

Technical Indicators

Highest since issue	0.3 CHF
Lowest since issue	0.03 CHF
Spread	0.01 CHF
Spread %	4.55%

Company Profile

Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (18%); - sale of animal health products (9.4%); - other (2.9%). Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).

Sector

More about the company